Nature’s Way acquires Baze, expanding its portfolio to personalized nutrition
Nature’s Way acquired Baze (Green Bay, WI), which offers an evidence-based approach to personalized nutrition through an at-home blood test.
Photo © iStockphoto.com
Nature’s Way (Boston, MA) acquired Baze (Green Bay, WI), which offers an evidence-based approach to personalized nutrition through an at-home blood test.
“Coming together with Nature’s Way is an exciting and logical next step for Baze, as we continue on our mission to provide our customers with products to improve their health and wellness through evidence-based, personalized nutrition,” said Philipp Schulte, co-founder and CEO of Baze, in a press release. “We strongly believe in the transformative impact personalized nutrition can have on our lives and are looking forward to being part of the Nature’s Way team.”
The blood test provides a snapshot of consumers’ micronutrient levels, used to recommend a custom supplement and food plan that eliminate 73% of customers’ nutrient deficiencies within three months.
“Personalized nutrition is an immense opportunity for us to expand on our mission of helping people live healthy lives,” said Mike Devereux, CEO of Nature’s Way, in a press release. “Combining the uncompromising quality of our products, with the industry-leading personalization capabilities at Baze, will create an outstanding new approach for anyone looking to further their health and wellness. Our teams are fully committed to continuing our leadership roles in quality and innovation in this growing consumer space.”
Kratom sees impressive sales growth despite its regulatory status and stigma
March 12th 2025Despite its controversy, kratom is a top-selling ingredient that consumers see value in. That said, brands need to work hard to demonstrate safety and quality of kratom products in the absence of legal regulatory status. Will kratom be able to overcome its stigma for even more growth and consumer acceptance?
DOJ asks Utah court to dismiss FTC lawsuit against Xlear Inc.
March 11th 2025On March 10, the DOJ and the defendant filed a stipulation to dismiss with prejudice the lawsuit in which each party agrees “to be responsible for its own costs and fees and agrees that no party shall be responsible to any other party for any fines, costs, fees, or penalties arising from this case.”
HHS announces efforts to eliminate independent conclusion of GRAS
Published: March 11th 2025 | Updated: March 11th 2025U.S. Department of Health and Human Services (HHS) Secretary, Robert F. Kennedy Jr., is directing the acting U.S. Food and Drug Administration’s (FDA) acting commissioner to explore rulemaking that would eliminate the independent conclusion of GRAS provision.
